Compare Walt Disney Co (DIS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs Merck & Co., Inc. — how do they compare? Walt Disney Co trades at $107.88 (market cap $184.79B), while Merck & Co., Inc. trades at $144.98 (market cap $351.28B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and Merck & Co., Inc. for 98 Days on average.
| DIS | MRK | |
|---|---|---|
Market Cap | $184.79B | $351.28B |
Volume | 13,033,550 | 7,969,665 |
Sector | Media | Health |
52-Week High | $116.65 | $156.43 |
52-Week Low | $92.40 | $82.49 |
Typical Hold Time | 199 Days | 98 Days |
Enterprise Value | $225.65B | $398.04B |
Dividend Yield | 1.4% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $104.76, up 0.7% with a bullish technical signal supported by moving averages. The company shows strong fundamental momentum with three consecutive quarterly earnings beats and robust revenue growth reaching $94.43 billion in 2025. Disney's net income margin expanded significantly to 13.13% while maintaining a reasonable P/E ratio of 22.07. Recent news highlights the company's $60 billion parks investment and streaming margin improvements above 13%.
Disney presents a compelling investment case with analyst consensus pointing to 20% upside to the $125.67 price target. The company's diversified entertainment ecosystem and accelerating DTC profitability support growth, though risks include free cash flow pressure from elevated investments and competitive streaming landscape. Institutional sentiment remains positive with 62.5% buy ratings among 64 analysts covering the stock.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
